---
anonymous_label: OUT-26
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 91e273c1a4c9154516a6bf9525799057997e47ef46a75753d43fe2a31113b702
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-26

### Recommendation: Run the Claim File Review

You should recommend the **Claim File Review**.

#### Reasoning
Your current data is "noisy" and likely misleading. You are seeing a classic case of **lagging indicators (bookings/renewals) masking leading failures (usage patterns).**

1.  **The Revenue Mirage:** The 16% expansion rise is contaminated by a "bundle price" incentive. You aren't measuring the value of SignalPath; you are measuring the effectiveness of a discount strategy.
2.  **The Usage Mirage:** A 39% increase in usage is a vanity metric if the activity is primarily managers auditing closed files. This is "administrative usage," not "operational value."
3.  **The Adoption Gap:** The behavior of front-line adjusters (high initial use, then abandonment) suggests the tool provides a "novelty spike" but fails to integrate into the daily habit of claims handling.
4.  **The Compliance Wall:** In health-liability, the "explainability" gap is a fatal flaw. If an adjuster cannot defend a recommendation to a reviewer, the software becomes a liability rather than an asset.

The **Usage Quality Sprint** is too superficial; it tracks *if* they return, not *why* the output was rejected. The **Commercial Cleanroom** is too risky; it tests sales psychology, not product utility, and could jeopardize the momentum the board currently sees.

The **Claim File Review** is the only option that addresses the "Ground Truth." By auditing actual files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (accepted vs. rewritten suggestions). This will tell you if SignalPath is actually solving the problem or if it is simply a "suggestion engine" that adjusters ignore once the novelty wears off.

#### The Tradeoffs
By choosing this, you are displacing **Scaling SignalPath Broadly**.

**What you give up:** You sacrifice the "momentum play." If SignalPath actually *is* a hit and you are just being overly cautious, you lose the first-mover advantage to capture more market share while the executive team is bullish. You risk a "cooling off" period where Sales feels Product is slowing down the commercial engine.

#### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. It provides a "snapshot" rather than a real-time dashboard. There is a risk that the sample size will be too small to be statistically significant, leading the board to view the results as anecdotal while Sales continues to point at the (discount-driven) expansion bookings as "proof" of success.

#### Evidence That Would Change My Mind
I would pivot to **Narrowing the plan around regulated health-liability workflows** if the Claim File Review reveals that SignalPath’s core logic is fundamentally sound, but the "explainability" gap is the *only* reason for abandonment.

If the review shows that adjusters in non-regulated segments are also overriding suggestions (not just health-liability), the product has a general utility problem. But if non-regulated users are accepting suggestions at high rates and only health-liability users are struggling, the product is a success—it just requires a specialized "compliance/audit" layer to unlock its most lucrative and difficult segment.
